Chemed (NYSE:CHE) updated its FY 2019 earnings guidance on Monday. The company provided earnings per share guidance of $12.65-12.85 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $12.78. Chemed also updated its FY19 guidance to $12.65-12.85 EPS.
Several equities analysts have recently issued reports on the stock. Zacks Investment Research cut shares of Chemed from a hold rating to a sell rating in a research note on Thursday, May 9th. ValuEngine cut shares of Chemed from a buy rating to a hold rating in a research note on Wednesday, May 1st. Oppenheimer lifted their price objective on shares of Chemed from $340.00 to $370.00 and gave the stock an outperform rating in a research note on Tuesday, April 30th. Finally, Royal Bank of Canada lifted their target price on shares of Chemed from $313.00 to $318.00 and gave the stock a sector perform rating in a research report on Monday, February 25th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and two have given a buy rating to the company’s stock. Chemed currently has a consensus rating of Hold and a consensus price target of $347.00.
Shares of Chemed stock opened at $329.33 on Wednesday. The firm has a market capitalization of $5.33 billion, a PE ratio of 27.61, a PEG ratio of 2.97 and a beta of 1.18. The company has a quick ratio of 0.70, a current ratio of 0.73 and a debt-to-equity ratio of 0.17. Chemed has a 1-year low of $260.03 and a 1-year high of $335.99.
In other news, Director George J. Walsh III sold 1,000 shares of the company’s stock in a transaction dated Monday, February 25th. The stock was sold at an average price of $328.07, for a total value of $328,070.00. Following the completion of the sale, the director now directly owns 7,663 shares of the company’s stock, valued at approximately $2,514,000.41. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Kevin J. Mcnamara sold 6,000 shares of the company’s stock in a transaction dated Monday, May 6th. The shares were sold at an average price of $331.67, for a total value of $1,990,020.00. Following the completion of the sale, the insider now directly owns 159,334 shares of the company’s stock, valued at $52,846,307.78. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 21,245 shares of company stock valued at $6,955,533. 3.96% of the stock is currently owned by company insiders.
ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by Rockland Register and is owned by of Rockland Register. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The correct version of this piece of content can be accessed at https://rocklandregister.com/2019/05/15/chemed-che-updates-fy-2019-earnings-guidance.html.
Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers in the United States. It operates through two segments, VITAS and Roto-Rooter. The company also offers plumbing, drain cleaning, water restoration, and other related services to residential and commercial customers through company-owned and independent contractors, and franchised locations.
Read More: The risks of owning bonds
Receive News & Ratings for Chemed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed and related companies with MarketBeat.com's FREE daily email newsletter.